INR Dose Adjustment Calculator
Estimate warfarin dose modifications based on current INR relative to target therapeutic range. Provides percentage-based adjustment guidance and clinical action recommendations for supratherapeutic and subtherapeutic values.
Calculate INR Dose Adjustment
Enter the patient’s current INR, weekly warfarin dose, and target therapeutic range. This tool estimates a percentage-based dose adjustment and new weekly dose. It is intended as a starting guide — individual patient factors, interacting medications, and clinical context must inform final dosing decisions.
This calculator provides estimated guidance only. Warfarin dosing is highly individualised and influenced by genetics, diet, drug interactions, liver function, and comorbidities. All dose changes should be confirmed by the prescribing clinician and followed up with repeat INR testing within 3–7 days.
Understanding INR & Warfarin Dosing
The International Normalised Ratio (INR) is a standardised measure of the extrinsic coagulation pathway, derived from the prothrombin time (PT). It was introduced by the WHO in 1983 to allow comparison of anticoagulation intensity across laboratories using different thromboplastin reagents. An INR of 1.0 represents normal coagulation; higher values indicate progressively slower clotting.
Warfarin inhibits vitamin K epoxide reductase (VKORC1), reducing the hepatic synthesis of functional clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S. Because factor II (prothrombin) has the longest half-life (~60 hours), full anticoagulant effect takes 5–7 days to stabilise, and dose changes take 3–5 days to manifest in the INR.
INR Formula
INR = (PTpatient / PTmean normal)ISI
Where ISI is the International Sensitivity Index of the thromboplastin reagent used. An ISI of 1.0 is ideal; most modern reagents have ISI values between 0.9 and 1.4.
Dose Adjustment Principle
Adjusted dose = Current dose × (1 ± adjustment %)
Adjustments are typically made in 5–20% increments of the total weekly dose. Smaller changes (5–10%) are preferred for near-therapeutic INRs to avoid overcorrection and dose oscillation.
Key principle: The relationship between warfarin dose and INR is not linear — small dose changes can produce disproportionately large INR shifts, especially in patients who are sensitive to warfarin or have fluctuating vitamin K intake. Adjust conservatively and recheck within 5–7 days.
Dose Adjustment Guide by INR Range
The following table summarises recommended dose adjustments for patients with a target INR of 2.0–3.0. For patients with a higher target range (2.5–3.5), shift category boundaries by +0.5. These are consensus-based recommendations adapted from major guidelines including the ACCP and BSH.
| INR Range | Category | Suggested Action | Dose Change | Recheck INR |
|---|---|---|---|---|
| < 1.5 | Significantly subtherapeutic | Increase dose; consider bridging if high thrombotic risk | ↑ 15–20% | 5–7 days |
| 1.5 – 1.9 | Mildly subtherapeutic | Increase dose | ↑ 5–15% | 7–14 days |
| 2.0 – 3.0 | Therapeutic | No change | — | 4–6 weeks |
| 3.1 – 3.5 | Mildly supratherapeutic | Decrease dose or hold 1 dose then reduce | ↓ 5–15% | 7–14 days |
| 3.6 – 4.9 | Moderately supratherapeutic | Hold 1–2 doses, then reduce | ↓ 10–20% | 3–7 days |
| 5.0 – 8.9 | Significantly supratherapeutic | Hold warfarin; consider oral vitamin K (1–2.5 mg) if bleeding risk is high | ↓ 15–25% | 1–2 days |
| ≥ 9.0 | Critical | Hold warfarin; give oral vitamin K 2.5–5 mg; consider IV vitamin K / PCC / FFP if bleeding | Reassess from scratch | 12–24 hours |
The most common cause of dose oscillation is making changes that are too large. For an INR of 3.2 in a patient on a stable dose, a 5–10% weekly reduction is typically sufficient. Resist the urge to hold multiple doses for mildly elevated INRs — this often leads to a rebound subtherapeutic INR and a cycle of over- and under-anticoagulation.
Factors Affecting INR & Warfarin Response
Warfarin has one of the narrowest therapeutic indices of any commonly prescribed drug. Numerous factors can shift the INR independently of dose changes. Clinicians should systematically assess these factors before attributing an out-of-range INR solely to dose inadequacy.
Warfarin is metabolised primarily by CYP2C9 (S-warfarin, more potent) and CYP3A4/CYP1A2 (R-warfarin). Drugs that inhibit these enzymes raise INR, while inducers lower it. Common potentiators include amiodarone (can raise INR by 30–50%), fluconazole, metronidazole, trimethoprim-sulfamethoxazole, and omeprazole. Common reducers include rifampicin, carbamazepine, phenytoin, and St John’s wort.
Antiplatelet agents (aspirin, clopidogrel) and NSAIDs increase bleeding risk without raising the INR, creating a hidden danger at seemingly therapeutic levels. Always review the full medication list when an INR is unexpectedly out of range. New antibiotics are a particularly common culprit — they can alter gut flora and reduce endogenous vitamin K production, raising the INR within 3–5 days of initiation.
Vitamin K is the substrate that warfarin blocks. Significant changes in dietary vitamin K intake can shift the INR substantially. Green leafy vegetables (kale, spinach, broccoli, Brussels sprouts) are particularly rich in vitamin K1. The key clinical advice is not to avoid these foods, but to maintain a consistent intake from week to week.
Patients who suddenly adopt a vegetable-rich diet (e.g. seasonal dietary changes, New Year resolutions, or cultural fasting periods followed by feasts) are at particular risk of INR instability. Nutritional supplements and meal-replacement drinks may contain variable amounts of vitamin K. Alcohol intake also affects warfarin metabolism — acute binge drinking inhibits CYP enzymes and raises INR, while chronic heavy drinking induces them and lowers INR.
Genetic variants in CYP2C9 and VKORC1 account for approximately 30–40% of interindividual variability in warfarin dose requirements. CYP2C9 poor metabolisers (*2 and *3 alleles) require lower doses due to slower clearance of S-warfarin, and are at higher risk of supratherapeutic INRs during initiation. VKORC1 variants (particularly the -1639G>A polymorphism) alter sensitivity to warfarin at the target enzyme level.
Pharmacogenomic-guided dosing algorithms (e.g. from the International Warfarin Pharmacogenetics Consortium) are available and may be useful during initiation, though routine testing is not universally recommended. Certain ethnic populations have higher prevalences of sensitive genotypes — for example, East Asian patients typically require lower maintenance doses than European-descent patients.
The liver is where both warfarin metabolism and clotting factor synthesis occur. Hepatic impairment (cirrhosis, acute hepatitis, congestive hepatopathy) can raise INR through reduced clotting factor production even before warfarin is initiated. These patients are inherently more sensitive to warfarin and typically require lower doses with more frequent monitoring.
Other conditions that increase warfarin sensitivity include hyperthyroidism (accelerates factor catabolism), heart failure (hepatic congestion reduces metabolism), febrile illness (increased factor catabolism and reduced intake), and malabsorption syndromes (reduced vitamin K absorption). Hypothyroidism and nephrotic syndrome may reduce warfarin sensitivity and require higher doses.
Before adjusting the dose for an out-of-range INR, always ask about adherence. Missed doses are the most common cause of subtherapeutic INRs, while double-dosing (forgetting whether a dose was taken and taking another) is a frequent cause of mildly supratherapeutic values. Complex alternating-day regimens (e.g. 5 mg Monday/Wednesday/Friday, 2.5 mg other days) are particularly prone to patient error.
Simplifying the dosing schedule where possible — for example, by using consistent daily doses or half-tablet increments rather than complex alternating patterns — can improve time in therapeutic range (TTR) and reduce the need for frequent dose adjustments. Pill organisers and warfarin-specific dosing calendars are helpful interventions.
When an INR is unexpectedly out of range, use the mnemonic DIALS: Drugs (new medications or changes?), Intake (dietary vitamin K changes?), Adherence (missed or extra doses?), Liver (new hepatic insult or illness?), Sick (febrile illness, diarrhoea, vomiting?). Address the underlying cause before adjusting the warfarin dose.
Special Populations
Warfarin dose requirements and monitoring frequency vary significantly across patient populations. The following groups warrant particular attention when interpreting INR values and adjusting doses.
Cancer patients on warfarin require special attention. Malignancy itself creates a hypercoagulable state, while chemotherapy, liver metastases, and poor oral intake create unpredictable INR fluctuations. LMWH or DOACs are generally preferred for cancer-associated VTE. If warfarin is used, expect more frequent monitoring and dose adjustments.
Systematic Approach to an Out-of-Range INR
A structured approach ensures that dose adjustments are appropriate, underlying causes are addressed, and patient safety is maintained.
Before adjusting the dose, determine whether the patient has any signs or symptoms of bleeding (bruising, haematuria, melaena, gum bleeding, heavy menstruation) or thromboembolism (limb swelling, dyspnoea, chest pain, neurological deficits). Active bleeding at any INR level requires immediate clinical assessment and may warrant reversal, not just dose adjustment. Document the bleeding severity and any recent falls or trauma.
Apply the DIALS framework: Drugs — any new medications, stopped medications, or dose changes in the last 1–2 weeks? Intake — changes in dietary vitamin K or alcohol? Adherence — any missed or extra doses? Liver — new hepatic insult, illness, or right heart failure? Sick — febrile illness, diarrhoea, vomiting? If a transient cause is identified (e.g. a short course of antibiotics), you may choose to monitor more frequently rather than change the dose permanently.
Use the calculator above to estimate the percentage adjustment and new weekly dose. Round to the nearest practical tablet increment — warfarin is available in 0.5, 1, 2, 3, 4, 5, 6, 7, and 10 mg tablets (availability varies by country). Design a weekly schedule that minimises the number of different daily doses. For example, if the new weekly dose is 32.5 mg, consider 5 mg on 5 days and 3.75 mg on 2 days, or simplify to 4.5 mg daily (31.5 mg/week).
Schedule repeat INR testing based on the degree of deviation: mildly out of range (INR 3.1–3.5 or 1.5–1.9) — recheck in 1–2 weeks; moderately out of range (INR 3.6–4.9 or <1.5) — recheck in 3–7 days; significantly elevated (INR 5.0–8.9) — recheck in 1–2 days; critically elevated (INR ≥9.0) — recheck within 24 hours. Document the new regimen clearly and communicate the plan to the patient, including when to seek urgent medical attention.
Common Pitfalls & Limitations
A single mildly elevated or mildly low INR — especially one that is close to the therapeutic boundary — does not always require a dose change. INR variability of ±0.3 is common even on a stable dose due to assay variability, dietary fluctuations, and timing of the blood draw relative to the last dose. Making large dose adjustments based on a single reading often triggers a cycle of overcorrection. If the INR is only slightly out of range and the patient is asymptomatic with no clear precipitant, consider rechecking in 1–2 weeks before modifying the dose.
One of the most frequent mistakes in warfarin management is adjusting the dose without reviewing the medication list. A patient whose INR jumps from 2.5 to 4.8 after starting amiodarone does not simply need a warfarin dose reduction — they need a proactive, planned reduction of 30–50% at the time amiodarone is initiated, with close monitoring. Similarly, stopping an interacting drug (e.g. discontinuing an antibiotic) will shift the INR back, potentially rendering the “adjusted” dose subtherapeutic. Always determine whether the INR change is due to a temporary factor before making permanent dose changes.
Because factor II has a half-life of approximately 60 hours, the full effect of a dose change takes 5–7 days to be reflected in the INR. Checking the INR too soon after a dose adjustment (e.g. 1–2 days later for a routine change) may give a misleadingly stable reading, prompting clinicians to think the change was insufficient. Conversely, checking at the right time may reveal that the adjustment was excessive. Schedule recheck timing according to the degree of deviation, and avoid stacking multiple dose changes before the previous adjustment has taken full effect.
The INR is validated for monitoring vitamin K antagonists (warfarin, acenocoumarol, phenprocoumon) only. Direct oral anticoagulants (DOACs) such as rivaroxaban and apixaban can elevate the INR variably and unpredictably — a raised INR on a DOAC does not have the same clinical meaning as a raised INR on warfarin. Similarly, unfractionated heparin prolongs the PT/INR. When transitioning between anticoagulants, the INR may not accurately reflect the degree of anticoagulation. Follow specific transition protocols for each drug combination.
Dose adjustment decisions should consider both the thrombotic risk of subtherapeutic anticoagulation and the bleeding risk of supratherapeutic levels. Tools such as the HAS-BLED score can help quantify bleeding risk. A patient with a HAS-BLED score of 4 and an INR of 3.2 warrants more aggressive dose reduction than a patient with a HAS-BLED of 1 and the same INR. Similarly, bridging anticoagulation for a subtherapeutic INR is only appropriate for patients with genuinely high thrombotic risk (e.g. recent VTE, mechanical mitral valve), not for all patients with a low INR.
Quick Reference Summary
| Scenario | Action | Key Consideration |
|---|---|---|
| INR in range, stable | Continue current dose, recheck 4–6 weeks | Extend interval to 8–12 weeks if consistently stable |
| INR mildly high (3.1–3.5) | Reduce dose 5–10%, recheck 1–2 weeks | Consider no change if single reading with clear transient cause |
| INR moderately high (3.6–4.9) | Hold 1–2 doses, reduce 10–20%, recheck 3–7 days | Assess for bleeding; review medications |
| INR ≥ 5.0, no bleeding | Hold warfarin; consider oral vitamin K 1–2.5 mg | Vitamin K shortens time to therapeutic range |
| INR elevated with major bleeding | Hold warfarin; IV vitamin K 5–10 mg; PCC or FFP | This is a medical emergency — involve haematology |
| INR low (< 1.5), high thrombotic risk | Increase dose 15–20%; consider LMWH bridge | Bridging only for high-risk patients (recent VTE, mechanical valve) |
The Golden Rule: Adjust conservatively, recheck early, and always ask “why” before changing the dose. A well-investigated out-of-range INR is more informative than a reflexive dose adjustment.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S–e184S. DOI: 10.1378/chest.11-2295
- Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin — fourth edition. Br J Haematol. 2011;154(3):311–324. DOI: 10.1111/j.1365-2141.2011.08753.x
- International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenomic data. N Engl J Med. 2009;360(8):753–764. DOI: 10.1056/NEJMoa0809329
- Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S–198S. DOI: 10.1378/chest.08-0670
- Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84(3):326–331. DOI: 10.1038/clpt.2008.10
- Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115(21):2689–2696. DOI: 10.1161/CIRCULATIONAHA.106.653048
- Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–239. DOI: 10.1055/s-0038-1651587
- Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–1711. DOI: 10.1161/01.CIR.0000063575.17904.4E